IPOs

Ablynx IPO raises $200M for its nanobody platform effort

Belgian biotech Ablynx has lowered its share price but upsized the number of shares on offer in its US IPO, raising $200 million from its debut. And another $29 million could follow if the underwriters pick up their allotment of 1.7 million shares at the $17.50 price.

Ablynx had pencilled in a $150 million target when it filed the IPO at the beginning of this month. But these can be fast-moving figures these days as a long queue of biotechs turn to an eager investor group for more funds to do development work.

Ablynx’s European shares {$ABLX BB} surged 25% after the Belgian biotech reported at the beginning of the month that its lead drug for an ultra-rare blood clotting disease hit the primary and two key secondary endpoints in the pivotal Phase III study. And with the European application already under review with the mid-stage results, Ablynx has been lining up a US filing planned for next year.

Their drug caplacizumab targets acquired thrombotic thrombocytopenic purpura (aTTP), a disorder that triggers low platelet counts. In the Phase III study, researchers reported top-line results that included a significant (p=0.01) reduction in the time it took for the platelet counts to return to normal for the drug arm — a likely indicator for the prevention of microvascular thrombosis.

Sanofi recently signed up as the latest in a lineup of partners working with Ablynx, attracted to a platform tech for small “nanobodies” which are a sliver of the size of regular antibodies — making them better built for some diseases.

That deal started with a small €23 million, expanding out to more than €2.4 billion on the back end.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->